190TiP: ELUXA 1: Phase II Study of BI 1482694 (HM61713) in Patients (Pts) With T790m-Positive Non-Small Cell Lung Cancer (NSCLC) After Treatment With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI)

Journal of Thoracic Oncology - United States
doi 10.1016/s1556-0864(16)30299-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2012English

Phase 1 Trial of Dasatinib Combined With Afatinib for Epidermal Growth Factor Receptor- (EGFR-) Mutated Lung Cancer With Acquired Tyrosine Kinase Inhibitor (TKI) Resistance

British Journal of Cancer
Cancer ResearchOncology
2019English

Association of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment and EGFR Exon 19 Deletion With Frequency of the T790M Mutation in Non-Small Cell Lung Cancer Patients After Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

OncoTargets and Therapy
OncologyPharmacology
2019English

Early Radiographic Response to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations: A Prospective Study

Biomedical Journal
Medicine
2015English

The Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

2013English

P1.01-36 Thoracic Surgery in Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutant After Tyrosine Kinase Inhibitor Therapy

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Elderly Patients With Advanced Non-Small Cell Lung Cancer

Current Gerontology and Geriatrics Research
GerontologyGeriatrics
2010English

Comparison of the Characteristics of Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations and EGFR‑tyrosine Kinase Inhibitor Treatment in Patients With Non‑small Cell Lung Cancer From Different Ethnic Groups

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2020English

Low Body Mass Index Is an Independent Prognostic Factor in Patients With Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

World Journal of Oncology
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy